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Abstract
BACKGROUND—The lung allocation score (LAS) has led to improved organ allocation for 
transplant candidates. At present, the 6-minute walk distance (6MWD) is treated as a binary 
categorical variable of whether or not a candidate can walk more than 150 feet in 6 minutes. In this 
study, we tested the hypothesis that 6MWD is presently under-utilized with respect to 
discriminatory power, and that, as a continuous variable, could better prognosticate risk of waitlist 
mortality.
METHODS—A retrospective cohort analysis was performed using the Organ Procurement and 
Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) transplant database. 
Candidates listed for isolated lung transplant between May 2005 and December 2011 were 
included. The population was stratified by 6MWD quartiles and unadjusted survival rates were 
estimated. Multivariable Cox proportional hazards modeling was used to assess the effect of 
6MWD on risk of death. The Scientific Registry of Transplant Recipients (SRTR) Waitlist Risk 
Model was used to adjust for confounders. The optimal 6MWD for discriminative accuracy in 
predicting waitlist mortality was assessed by receiver-operating characteristic (ROC) curves.
RESULTS—Analysis was performed on 12,298 recipients. Recipients were segregated into 
quartiles by distance walked. Waitlist mortality decreased as 6MWD increased. In the 
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multivariable model, significant variables included 6MWD, male gender, non-white ethnicity and 
restrictive lung diseases. ROC curves discriminated 6-month mortality was best at 655 feet.
CONCLUSIONS—The 6MWD is a significant predictor of waitlist mortality. A cut-off of 150 
feet suboptimally identifies candidates with increased risk of mortality. A cut-off between 550 and 
655 feet is more optimal if 6MWD is to be treated as a dichotomous variable. Utilization of the 
LAS as a continuous variable could further enhance predictive capabilities.
Keywords
lung transplantation; 6-minute walk distance; organ allocation; candidate assessment; waitlist 
mortality
There has been significant progress in lung transplantation since its induction in 1963.1 As 
of 2008, nearly 3,000 lung transplants were performed each year.2 Despite this success, there 
have been numerous obstacles along the way. One such issue has been the determination of 
an ethical and productive means of allocating donor lungs, as supply of lungs has never 
equaled the demand. Before 1995, lung allocation was determined purely by waitlist time, a 
process that led to clinicians placing candidates on waitlists earlier than necessary in order to 
accrue time.3,4 In 1995, secondary to a high mortality rate among candidates with idiopathic 
pulmonary fibrosis (IPF), the Organ Procurement and Transplantation Network/United 
Network for Organ Sharing (OPTN/UNOS) added 90 days of accrued waiting time to 
candidates with IPF.3,5 It was not until 2005, however, as the number of candidates on the 
waiting list continued to flourish, that a major overhaul was performed.4,6,7
In May 2005, the lung allocation score (LAS) was instituted as a means to further decrease 
waitlist mortality and, to a lesser extent, avoid transplants in candidates with a low 
likelihood of survival and therefore diminished utility of transplantation.7 The LAS takes 
into account likelihood of survival on the waiting list and post-transplant survival, and is 
subsequently used to compute the overall benefit of lung transplant on an individual basis.7 
The estimation of these values was derived using retrospective models which found that 
variables such as diagnosis, forced vital capacity (FVC), age, body mass index (BMI) and 
New York Heart Association (NYHA) functional class, among others, were significant 
determinants of waitlist survival and/or post-transplant survival.7,8 Since its implementation, 
the LAS has (as designed) led to decreased transplant list waiting times and waitlist 
mortality. However, although measures of short-term survival (6 months and 1 year) have 
improved, there has been no demonstrable effect on overall long-term post-transplant 
survival.7,9–14 Further specific changes observed after implementation of the LAS have 
recently been reviewed in the latest OPTN/Scientific Registry of Transplant Recipients 
(SRTR) annual data report.7,9–14 Significant changes in the distribution of diagnoses among 
those receiving transplants has also been seen after implementation of the LAS, including a 
decrease in number of candidates with chronic obstructive pulmonary disease (COPD) and 
an increase in number of candidates with IPF.7,10,11 Further changes identified in reviews 
include an increase in candidates >65 of age receiving transplants, and a decrease in racial 
disparities among transplant recipients.15,16
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Despite the successes of the LAS, there remain significant shortfalls. As stated previously, 
there has been no significant increase in post-transplant survival after implementation.9–11 
Furthermore, there has been evidence that candidates with very high LAS scores do not 
necessarily have the same or increased transplant benefit as those with more moderate 
scores, raising the question of whether the LAS computation is appropriate.17 These findings 
may be secondary to how the LAS was developed, as it is weighted more heavily toward 
decreasing waitlist mortality than toward post-transplant survival.8 Some studies have 
recommended incorporation of new variables into the LAS or the adjustment of thresholds 
for variables already in use and, although the LAS was designed to allow modernization, few 
of these changes have occurred.8,18–20
One such variable that requires re-evaluation is the 6-minute walk distance (6MWD).21 
Although inconsistencies in the manner of which the test is conducted can produce 
discrepancies in results, the test has been shown to predict mortality in numerous disease 
processes, including pulmonary arterial hypertension (PAH), IPF, and even liver failure.22–27 
The 6MWD also provides discriminatory power in outcomes after pediatric lung 
transplantation.28 It is therefore a valuable predictor of waitlist survival. The current use of 
the 6MWD within the LAS is as a binary categorical variable; that is, whether or not the 
candidate can walk >150 feet in 6 minutes.29 Despite its use in the LAS, studies have 
demonstrated that this may be too short a distance to appropriately differentiate candidates 
with increased risk of waitlist mortality.30,31 Due to the continued use of 150 feet as a 
threshold for the 6MWD within the LAS, we have investigated the 6MWD to determine the 
appropriate cut-off that could best distinguish candidates who have an increased risk of 
waitlist mortality.
Methods
The institutional review board (IRB) at Duke University approved this study before data 
collection.
Data source
A retrospective cohort analysis was performed using the OPTN/UNOS transplantation 
database. This database contains data on all transplant candidates undergoing organ donation 
and transplant in the United States since October 1987. The data set used for this 
investigation included all recipients receiving lung transplantation between October 1987 
and December 2011. As of 1999, all data in the OPTN/UNOS database are collected via an 
internet-based database application called “UNet.” Data are entered by transplant 
professionals. Electronic data validation and on-site audits are performed for quality 
assurance.32
Study design
All transplant candidates who were listed for isolated lung transplant between May 2005 and 
December 2011 were included. Exclusion criteria included pediatric candidates (those <12 
years of age) and candidates missing data for the 6MWD variable or who had “0” listed as 
the result. The primary predictor variable used in this study was 6MWD. Covariates were 
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used to adjust for variation, including: age; diagnosis; gender; functional status; LAS; 
insurance status; education level; and other medical comorbidities. The primary outcome 
variable was waitlist mortality.
Recipients transplanted off the waitlist were censored at the time of transplant. Secondary 
analyses were performed for subgroups based on initial diagnosis.
Statistical analysis
Demographic data was compiled and described. The study population was stratified by 
6MWD quartiles and unadjusted recipient survival rates were estimated using the Kaplan–
Meier method and compared with the log-rank test. Multivariable Cox proportional hazards 
modeling was used to assess the effect of 6MWD on risk of death. The variables included in 
the SRTR Waitlist Risk Model were used to adjust for confounders. The optimal 6MWD for 
discriminative accuracy in predicting waitlist mortality was then assessed by constructing 
receiver-operating characteristic (ROC) curves. p ≤ 0.05 was considered significant for all 
analyses performed in this study. Analyses were performed using JMP version 10.0 (SAS 
Institute, Inc., Cary, NC) and R version 2.15.1 (R Core Team, Vienna, Austria).
Results
Analysis was performed on 12,298 transplant recipients from an initial cohort of 39,968. 
The study inclusion/exclusion algorithm is shown in Figure 1. Demographic data from the 
study population are listed in Table 1. Candidates were divided into quartiles by distance 
walked and unadjusted Kaplan–Meier survival curves were generated (Figure 2). As 6MWD 
increased, a statistically significant decrease in waitlist mortality was observed. Candidates 
were subsequently partitioned by distance walked in intervals of 200 feet, and average 
waitlist mortality was assessed (Figure 3). Although no statistical significance was 
calculated, a general downward trend can be seen as distance walked increased.
Using multivariable Cox proportional hazards modeling, candidate characteristics were used 
to predict risk of waitlist mortality (Table 2). Significant variables included 6MWD, male 
gender, non-white ethnicity and restrictive lung diseases. ROC curves were developed to 
evaluate an appropriately discriminatory 6MWD cut-off for both 30-day (Figure 4) and 6-
month (Figure 5) mortality. The 30-day mortality was best discriminated at a distance of 550 
feet, whereas 6-month mortality was best discriminated at 655 feet. As a sub-group analysis, 
we also analyzed 30-day mortality for IPF using the ROC curve (the most common 
transplant diagnosis), which resulted in a cut-off distance of 765 feet (Figure 6).
Discussion
Lung allocation has seen significant advancements over the past 3 decades, including most 
notably the introduction of the LAS in May 2005.3,4,7 The LAS was constructed using Cox 
proportional hazards models for both waiting list mortality and post-transplant survival, 
which together help derive the transplant benefit.7 Multiple variables found to be significant 
predictors of both waiting list mortality and post-transplant survival were included in the 
equation to derive the LAS.33 Introduction of the LAS has re-distributed allografts such that 
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waitlist mortality initially increased, and now varies significantly by age and diagnosis 
group.9–11 Furthermore, candidates with high LAS do not necessarily have the associated 
transplant benefit compared to candidates with a more moderate LAS, likely secondary to a 
stronger weighting of the LAS toward decreasing waitlist mortality over increasing post-
transplant survival.8,12,17,34 Despite a built-in mechanism for the re-evaluation and addition 
of variables to the LAS over time, there have been few adjustments since 2005.8
One variable of the LAS that has received attention in previous studies is use of the 6MWD. 
These studies have specifically hypothesized that the 6MWD cut-off may be too low to 
adequately predict waitlist mortality.31,35 In addition, in its present form, the distillation of 
the 6MWD into a dichotomous variable may under-utilize the discriminatory power of the 
test. The treatment of 6MWD as a continuous variable may add significant discriminatory 
power, although it may further complicate calculation of the LAS. Our findings agree with 
those of previous studies showing that the 6MWD is a significant predictor of 
mortality.23,25,26 Furthermore, our findings agree that 150 feet is too low a cut-off to 
properly determine which candidates have an increased risk of waitlist mortality.31,35 
Through the use of ROC curves, we found that a cut-off of between 550 and 655 feet (for 
30-day and 6-month mortality, respectively) is more optimal, depending on whether 30-day 
or 6-month mortality is used. The utility of ROC curves helps to determine how to maximize 
both the sensitivity and specificity of a cut-off point, thus providing a more optimal clinical 
value.36 Therefore, through the use of ROC curves, we have shown that a high cut-off for the 
6MWD within the LAS will provide both a more sensitive and specific means of predicting 
waitlist mortality. Although this hypothesis has been presented in previous studies, none 
have taken into account a sample size of this magnitude or a scope of candidates of this 
breadth.
Our study also raises many questions with regard to the use of the 6MWD within the LAS. 
First, the dichotomization of a continuous variable reduces the power of that variable.37–40 
As a binary variable, candidates are graded solely on their ability to walk a specific target 
distance. This severely limits the ability of the test to discriminate between candidates. For 
instance, there is no difference in the 6MWD result within the LAS for a candidate who can 
only walk a minimal distance with one who can just barely make the cut-off. Based on the 
data in the present study, however, if used as a continuous variable, the 6MWD would have 
an increased predictive ability to determine waitlist mortality up to a 6MWD of nearly 1,200 
feet. After 1,200 feet, 6MWD appears to lose its discerning features for 6-month waitlist 
mortality.
Another question to consider is how different diagnoses affect the findings derived from the 
ROC curves. We demonstrated in this study that the best cut-off for the 6MWD when 
comparing for 30-day mortality for IPF candidates is 765 feet, compared with 550 feet for 
the general population. This is likely secondary to worse outcomes associated with IPF when 
compared with other diagnoses.5 Although diagnosis is already taken into account within the 
LAS, it is not known whether this satisfactorily accounts for the differences in the 6MWD, 
or if it should be taken into account a second time to make the 6MWD cut-off more 
accurate.7,33
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Although the 6MWD was initially included in the LAS only as a predictor of waitlist 
mortality, we have shown in a previous investigation that the 6MWD is also significantly 
associated with post-transplant survival.7,41 As the goal of the LAS is to minimize waitlist 
mortality and avoid a futile transplant, each contributing variable should be thoroughly 
optimized to best provide this discriminatory power. The goal is to optimize variables with 
respect to prediction of both who will survive on the waitlist the longest, as well as who will 
survive after transplant. By minimizing waitlist mortality while maximizing post-transplant 
survival, the transplant benefit can be exhausted. If, however, a variable predicts both, then 
its use in predicting waitlist mortality may cancel out its use in predicting post-transplant 
survival. Furthermore, if 6MWD is a predictive variable for both outcomes, and we intend to 
place more importance on reducing waitlist mortality over maximizing post-transplant 
survival, then more discussion will be needed to determine how this impacts the most 
appropriate way to include 6MWD in the allocation score.
Despite the significance of our study, there are certain limitations that should be noted. First, 
previous data demonstrated that inconsistencies in how the 6MWD is recorded can lead to 
significant variation.22 Based on how the data are recorded, we cannot adjust for these 
variations, and it is possible that they may have an effect on outcome. Second, we cannot see 
trends in the LAS to determine how candidates have progressed, and where along this 
progression their LAS was calculated. This could theoretically lead to a higher average 
6MWD since induction of the LAS, which may explain why a much lower cut-off was 
initially derived. Last, given the retrospective nature of this study, there remains the 
possibility of potential confounders for which we cannot account.
In conclusion, although use of the LAS has led to significant positive results, especially with 
regard to decreasing waitlist times, there are still many issues that need to be resolved.9,10 
As described in our study and noted elsewhere, altering the threshold for the 6MWD as a 
dichotomous variable within the LAS would have better predictive ability to determine who 
has a higher chance of mortality while awaiting a lung transplant.31,35 Furthermore, utilizing 
the LAS as a continuous variable may further enhance its predictive capabilities. By 
improving the ability of the LAS to discriminate waitlist survival, we can ensure that 
utilization of the limited supply of donor lungs is as efficient as possible. Continued 
investigation of current and new predictors of mortality is necessary to ensure that utilization 
of the LAS remains as beneficial as possible.
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Figure 1. 
STROBE diagram of candidates analyzed. STROBE, strengthening the reporting of 
observational studies in epidemiology. WL, waitlist; 6MWD, 6-minute walk distance.
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Figure 2. 
Kaplan–Meier curves for each 6MWD quartile.
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Figure 3. 
Six-month waitlist mortality per interval in the 6MWD (each interval contains 200 feet).
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Figure 4. 
ROC demonstrating optimal cut-off for 6MWD based on 30-day waitlist mortality. AUC = 
0.81289.
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Figure 5. 
ROC demonstrating optimal cut-off for 6MWD based on 6-month waitlist mortality. AUC = 
0.67380.
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Figure 6. 
ROC demonstrating optimal cut-off for 6MWD based on 30-day waitlist mortality for IPF 
candidates. AUC = 0.71246.
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Table 1
Baseline Characteristics (N = 12,298)
Characteristic
Age, in years (range) 57 (48 to 63)
Age = 60 5,045 (41.0%)
Female gender 5,654 (46.0%)
Race
 White 10,222 (83.1%)
 Black 1,121 (9.1%)
 Hispanic 687 (5.6%)
 Asian 188 (1.5%)
 Other/unknown 80 (0.7%)
Diagnosis
 Obstructive 4,317 (35.1%)
 Pulmonary vascular 553 (4.5%)
 CF or immunodeficiency 1,378 (11.2%)
 Restrictive 6,050 (49.2%)
Recipient comorbidities
 Diabetes 2,303 (18.9%)
 Hypertension 443 of 1,766 (25.1%)
 Cerebrovascular disease 16 of 1,776 (0.9%)
 Creatinine at transplant (n = 1,780) 0.8 (0.7 to 1.0)
 BMI (kg/m2) at listing (n = 8,471) 25.3 (21.4 to 28.9)
Pre-transplant status (n = 1,798)
  Hospitalized 95 of 1,799 (5.3%)
 Intensive care unit 67 of 1,796 (3.7%)
 Requiring life support at listing (n = 8,481)a 233 of 8,473 (2.8%)
 Requiring ventilator at listing 219 (1.8%)
Pulmonary function and hemodynamics at listing
 Initial lung allocation score (n = 11,631) 35.9 (33.0 to 41.8)
 Oxygen requirement (liters) (n = 1,652) 3.0 (2.0 to 4.0)
 FEV1, % predicted (n = 1,754) 30 (20 to 49)
 FVC, % predicted (n = 1,765) 48 (37 to 61)
 FEV/FVC (n = 1,753) 0.73 (0.43, 1.06)
 Mean PA pressure (mm Hg) (n = 11,085) 25 (20 to 31)
Recipient insurance at time of transplant
 Private/Self 7,159 (58.3%)
 Medicaid 950 (7.7%)
 Medicare 3,776 (30.8%)
 Other 391 (3.2%)
Education level (n = 10,892)
 Grade school or lower 342 of 10,892 (3.1%)
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Characteristic
 High school or GED 4,550 of 10,893 (41.8%)
 Attended college or technical school (no degree) 2,899 of 10,890 (26.6%)
 College degree or higher 3,101 of 10,892 (28.5%)
 Smoking history (>10 pack-years) (n = 5,684) 875 of 5,686 (15.4%)
Data expressed as median (interquartile range) for non-parametric continuous variables and as number (%) for categorical variables. If data are 
missing for >5% of the study population, the denominator is given for categorical variables and number (n) given for continuous variables. BMI, 
body mass index; CF, cystic fibrosis; FEV1, forced expiratory volume at 1 second (%); FVC, forced vital capacity; GED, general equivalency 
degree; PA, pulmonary artery.
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Table 2
Multivariable Cox Proportional Hazards model Predictors of Waitlist Mortality
Cumulative risk of death
Characteristics AHR (95% CI) p-value
6MWD (per 200-foot increment 0.77 (0.75 to 0.79) <0.001a
Recipient age (per 5-year increase) 1.01 (0.98 to 1.03) 0.54
Male gender (reference: female) 1.16 (1.04 to 1.28) 0.006a
Non-white ethnicity (reference: white) 0.87 (0.77 to 0.99) 0.036a
Restrictive lung disease (reference: obstructive) 3.33 (2.93 to 3.79) <0.001a
Type O blood (reference: AB) 0.78 (0.59 to 1.01) 0.061
6MWD, 6-minute walking distance; AHR, adjusted hazard ratio; CI confidence interval.
aStatistically significant at p ≤ 0.05.
J Heart Lung Transplant. Author manuscript; available in PMC 2017 July 03.
